Full Text View
Tabular View
Study Results
Related Studies
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
This study has been terminated.
( See Detailed Description )
Study NCT00445328   Information provided by Pfizer
First Received: March 7, 2007   Last Updated: October 5, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Venous Thromboembolism
Additional conditions recognized in this trial
Thromboembolism
More general conditions related to this trial
Cardiovascular Diseases
Embolism and Thrombosis
Thrombosis
Vascular Diseases
Interventions listed in this trial
Dalteparin (Fragmin)
Unfractionated heparin
Additional drug interventions recognized in this trial
Calcium heparin
Dalteparin
Heparin
Heparin, Low-Molecular-Weight
More general drug interventions related to this trial
Anticoagulants
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services